GreenLight Biosciences is making cheaper, commercial level production of mRNA a reality for vaccines.

Founded in 2008, Boston-based GreenLight Biosciences says it has developed a commercial method to produce mRNA for both life and plant sciences applications without the use of cells.

CEO Andrey Zarur penned an op-ed for STAT urging the biotech industry to collaborate. “Now is not the time for those involved in developing and manufacturing the COVID-19 vaccines to hold their cards tightly to their chests. We must work together and commit to helping each other.”